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Purpose: As the molecular basis of congenital heart disease (CHD) comes into sharper focus, cardiac 
genetics services are likely to play an increasingly important role. This study aimed to identify parents’ 
preferences for, and willingness to participate in, clinical genetics services for CHD. 
Methods: A discrete choice experiment (DCE) was developed to assess parents’ preferences for pediatric 
cardio-genetics services described by four attributes: appointment format, health professionals involved, 
waiting time, and information format. Data were analyzed using a mixed logit model.  
Results: One-hundred parents of a living child diagnosed with CHD requiring surgical intervention 
between 2000-2009 completed the DCE. Parents expressed a clear preference for cardiac genetics 
services featuring: (a) one appointment, (b) with both a clinical geneticist and genetic counselor, (c) 
providing verbal and web-based information about CHD and genetics, (d) within two weeks. If offered 
this service, 93% of respondents indicated they would attend. The choice of cardiac genetics service was 
most strongly influenced by the presence of both a clinical geneticist and genetic counselor. 
Conclusion: Parents of children with CHD favor a single, timely genetics appointment with both a 
geneticist and genetic counselor present. If offered an appointment matching their preferences, uptake is 
likely to be high. 
 








Congenital heart disease (CHD), a spectrum of structural anomalies of the heart, affects one in 110 
newborns or 1.35 million babies worldwide each year, and represents a major global health burden.1 CHD 
is the most common cause of neonatal admission to pediatric intensive care,2 and a leading cause of infant 
death3 and disease‐related disability in children under age five years.4 Survival has markedly improved 
over the past two decades, and best estimates suggest there are now well over 65,000 people in Australia 
and 2 million people in the United States living with CHD.5,6  
 
Understanding of the genetic contributions to CHD is rapidly evolving. Chromosomal microarray 
(CMA)7 and massively parallel sequencing (MPS)8 technologies have made significant inroads, in terms 
of both CHD diagnosis and our understanding of the mechanisms underlying this disease. In individuals 
with familial CHD, for example, the chance of achieving a molecular diagnosis with MPS is now 31-
46%.9,10 In individuals with sporadic CHD, de novo variation in known or novel CHD genes has recently 
been identified in a small proportion (~10%) of cases.11 The genetic link between heart and brain 
development has also been established beyond the well-known genetic syndromes, expanding our 
knowledge of the mechanisms underlying the heightened vulnerability to neurodevelopmental impairment 
in children with CHD.12  
 
As the molecular basis of CHD comes into sharper focus, cardiac genetics services are likely to play an 
increasingly important clinical role. The American Heart Association Scientific Statement on the genetic 
basis for CHD recommends the approach to all newly diagnosed patients includes routine examination of 
all relatives for a potential genetic contribution.13 Within an interdisciplinary team approach,13 cardio-
genetics services require input from clinical geneticists specializing in the medical evaluation of people 
with CHD, and genetic counselors skilled in providing tailored education on inheritance, recurrence risk, 
risk management and family screening, as well as counseling to support informed decision-making and 




implications for psychological and behavioral adjustment and family planning, and can also have 
important implications for clinical management and family screening. Individuals with variants in specific 
genes known to be associated with development of conduction abnormalities or cardiomyopathies, such 
as NKX2-5, TBX5, and TBX20, are key examples.15-17 Individual genetic variation may also influence 
post-surgical outcomes including post-operative tachycardia,18 tolerance to ischemic and re-perfusion 
injury,19 neurocognitive impairment,20 and risk of death or transplantation.21 These findings suggest 
molecular diagnosis may lead to improvements in patient quality of life, and potentially even survival. 
Expanding application of genetic technologies also creates a growing need to assist individuals and 
families in navigating the complexities associated with incidental findings, or findings of uncertain 
clinical significance.22,23  
 
While referral to cardiac genetics services is still relatively uncommon in day-to-day pediatric 
cardiology,24 it is imperative we develop a deeper understanding of parents’ perceptions of, and 
preferences for, such services.25 In an earlier study,24 we found most parents of a child with CHD (87%) 
perceived genetic factors as ‘quite’ or ‘extremely important’ in CHD development and many (73%) 
wanted information about CHD and genetics; however, only 36% of participants could recall receiving 
genetics information, most commonly from a pediatric cardiologist (73%) or website (56%).24 Moreover, 
we found only 22% of families had previously accessed pediatric cardio-genetics services, with the 
presence of a syndrome associated with CHD (OR=17.93; p<0.001) and fetal cardiac diagnosis (OR=4.13; 
p=0.02) most strongly influencing attendance.24 More recently, we found almost all parents (98%) 
perceived information on CHD recurrence risks as important, yet only 7% could recall receiving this 
information from a health professional.26 Individualized genetic counseling sessions tailored to CHD have 
been shown to be highly beneficial for parents of children with CHD, with improvements in parents’ 
knowledge of CHD causation and enhanced psychological wellbeing, including greater perceived 




evidence-based models for the implementation of interventions such as these into clinical practice is a 
logical and much-needed next step.  
 
Important when designing health services is to understand how individuals make healthcare choices, and 
what aspects of a health service they value most. Discrete choice experiments (DCE) are one means of 
investigating preferences for goods and services, and are increasingly used in health services research,e.g.27 
particularly when there is limited evidence on potential engagement with new services. In a DCE, 
respondents are asked to choose between a series of alternatives (or profiles) that present different health 
services or interventions. Services are described in terms of their characteristics (or attributes); for 
example, who provides the health service, and in what form. By systematically varying the combinations 
of attributes presented in each alternative, and asking respondents to choose their preferred option, the 
analysis of these repeated choices shows how individuals tradeoff between attributes when making their 
choice, hence describing their preferences for those attributes.28   
 
To our knowledge, there are no published studies examining the preferences of parents of children with 
congenital heart disease for genetics services tailored to CHD. The primary aim of this study was to apply 
DCE methodology to estimate parents’ preferences for clinical genetics services for CHD. A secondary 
aim was to examine the likelihood that parents would attend their preferred cardiac genetics service.  
 
MATERIALS AND METHODS 
Participants 
Parents or guardians of a living child diagnosed with CHD between 2000-2009 and who had undergone 
cardiac surgery were identified via the Department of Cardiology databases at the Sydney Children’s 
Hospital, Australia. Parents of children with heritable heart diseases (e.g., aortopathy, inherited 




for participation if they were aged >18 years and could participate in English. To limit burden on families, 
one parent per family was invited, with the choice regarding who took part left up to each family.  
 
Procedure 
The study was approved by the South Eastern Sydney Illawarra Area Health Service Human Research 
Ethics Committee (HREC) (Approval Number: 08/202) and informed consent was obtained for all 
participants. A study package comprising an invitation letter from the child’s pediatric cardiologist, 
participant information sheet, questionnaire and reply-paid envelope was mailed to all eligible families. 
Reminder letters and telephone calls were made, as appropriate, to parents who did not return the 
questionnaire within one month. Due to stipulation from the HREC, no further attempts were made to 
contact families after one telephone conversation and a second mailout. St 
 
Discrete Choice Experiment Design 
A DCE was developed specifically to assess parents’ preferences for various attributes of a hypothetical 
pediatric cardio-genetics service. A systematic review of the literature and consultation with experts from 
various fields (clinical genetics, genetic counseling, pediatric cardiology, medical psychology, health 
economics) informed the choice of four attributes included in the DCE (appointment format, health 
professionals involved, waiting time, information format), each with three possible levels (see Figure 1 
for an example choice set and Supplementary Table A for the full list of attribute levels). From the initial 
81 possible choice combinations in the full factorial, a fractional orthogonal design comprising nine 
choice sets was selected and tested using online design software.29 Each respondent was presented with 
all nine choice sets. Prior to completing the choice sets, respondents were provided with a description of 
the context in which they were being asked to choose between options for CHD genetic risk assessment, 
and a description of each of the attributes and levels. Respondents could refer back to these definitions 
when needed. At each choice set, respondents were asked to indicate which appointment type they 




offered (Error! Reference source not found.). Prior to administration, the DCE was pilot-tested with a 
convenience sample of five parents of a child with CHD. Results showed the DCE was easy to understand 
and complete, and required no modification.  
 
[Insert Figure 1 about here] 
 
Demographic and Clinical Characteristics  
Seven demographic items assessed: parent age, education, gross annual household income (categorized as 
above or below the National average based on the Australian Survey of Income and Housing30), 
birthplace, language most commonly spoken at home, relationship to the child with CHD (e.g. mother), 
and residence at time of childbirth. Participants were asked if their child had been diagnosed with, or if 
they suspected their child had, a chromosomal abnormality or syndrome, and if they had previously 
attended a genetics service to discuss their child’s heart condition. 
 
Statistical Analysis 
DCE analysis exploits the relationship between respondents’ choices and the choice profiles, revealing the 
impact on choice of differences between the attributes for the options being compared.27,28 Our analysis 
adopted this approach, focusing on the mean choice coefficients across respondents using a  
multinomial logit analysis, then a mixed logit analysis to incorporate the extent to which there was 
heterogeneity across respondents in what influenced their choices.28,31 Heterogeneity in preferences was 
explored by applying the method described by Hole,31 which estimates the extent to which attributes 
influence choice (reported as means), as well as the extent to which respondents differ in the influence of 
those attributes (reported as the standard deviation around each attribute mean). For each multinomial 
logit and mixed logit analysis, we specified models with and without a constant, to test whether 
respondents were systematically choosing the left or right-hand profile in each choice set (the columns 




completed all nine choice sets were included in the analysis. The impact on the results of excluding 
respondents who completed fewer than nine choice sets was tested in a sensitivity analysis. An additional 
sensitivity analysis was carried out to examine the impact on preferences of respondents having 
previously attended a cardiac genetics service.    
 
An important output from DCE analyses is the ability to predict the likelihood that individuals will use 
the service under investigation.28 In the present study, the likelihood of service use was examined using 
the results of the mixed logit analysis, using pairwise comparisons to estimate the probability that 
respondents would use one of four new service models compared with the current approach to cardiac 
genetics service provision. The four new service models included one featuring the combination of the 
most influential levels for each attribute, and three other service models based on plausible combinations 
of the remaining attribute levels (see Table 2 for a description of each service). All analyses were carried 
out using StataCorp software, Stata 12 (Texas, USA). 
 
RESULTS 
Response rates and sample characteristics 
Two-hundred fifty-seven eligible families were identified. Of these, 44 families were not contactable 
(incorrect address, disconnected telephone), 21 families declined participation, and 78 families did not 
return the questionnaire, resulting in 114 returned questionnaires; a participation rate of 53.5% among 
eligible, contactable families (114/213). Participants and non-participants did not differ according to child 
age (p=0.90), child sex (p=0.50), or presence of single ventricle CHD (p=0.29). 
 
A total of 100 individuals (87.8% of 114 participants) completed all nine DCE choice sets. The mean age 
of respondents was 36.4 years (SD=5.4), the majority were mothers (80.0%), most were born in Australia 
(79.0%) and predominantly spoke English at home (90.0%). One-quarter of respondents (24.0%) had 




syndrome. Of those who had no previous exposure to cardiac genetics services, less than one-third 
(29.3%) could recall receiving information about CHD and genetics, and for those who could, the most 
common information sources were a pediatric cardiologist (22.4%), the internet (22.4%) and/or a leaflet 
(14.5%). Participants who did not complete all choice sets (12.2%) differed from those who did in terms 
of several demographic characteristics (Table 1). The implications of these differences for understanding 
respondents’ preferences were tested in a sensitivity analysis. 
 
[Insert Table 1 about here] 
 
Understanding Choices 
Results of both the multinomial logit and mixed logit analyses showed respondents were more likely to 
choose a cardiac genetics service involving: (i) only one appointment, (ii) with both a clinical geneticist 
and genetic counselor, (iii) providing web-based as well as verbal information about CHD and genetics, 
and (iv) available within two weeks (Error! Reference source not found. and Supplementary Table B). 
These were the attribute levels with the greatest positive influence. Model fit statistics (log-likelihood and 
R2) indicated the mixed logit was a better representation of the choice data (Supplementary Table B). 
Based on Model 3, for example, we observed that offering an appointment with both a clinical geneticist 
and genetic counselor increased the likelihood of choosing the service by 1.54 (p<0.01) relative to the 
presence of a clinical geneticist only.  
 
[Insert Figure 2 about here] 
 
Results from the mixed logit analysis also indicated that respondents differed in the extent to which they 
were prepared to tradeoff between the attributes; the significant standard deviations on all attributes 
demonstrate preference heterogeneity among respondents. This was most evident for the number of 




appointment only, while 23% of participants preferred an ongoing appointment compared with one 
appointment only. While most participants preferred having both clinician types present at their 
appointment, 1% of participants reported a preference for a clinical geneticist only. Respondents also 
differed in how they were influenced by the 6-week waiting time compared with 6 months; 56% of 
participants preferred the shorter waiting time, while 44% of participants preferred the longer waiting 
time. Finally, respondents differed in how information format influenced preferences; 36% of participants 
reported a preference for information presented verbally and in a booklet, compared with verbally alone. 
Respondents were consistent in how they viewed the tradeoffs between other attribute levels. 
 
Sensitivity Analyses 
Sensitivity of the results to variation in model structure, whether respondents completed all choice 
questions, and previous exposure to cardiac genetics services was tested. First, the inclusion of a constant 
term in Models 2 and 4 suggested that some respondents displayed a preference for the option that 
appeared on the right-hand side of the task (‘Appointment B’). Given that: (i) the choice coefficients in 
these models did not differ from those in Models 1 and 3, (ii) a constant was not included in the 
underlying DCE design, and (iii) the experiment did not include an opt-out option, the main results 
reported are those from Models 1 and 3. The results examining potential differences in preferences based 
on whether or not all choice sets were completed, and prior cardiac genetics service attendance confirmed 
the choice preferences observed in the main analysis; thus, we did not identify any systematic differences 
in responses between participants who had versus had not previously attended a pediatric cardio-genetics 
service (results available upon request).  
 
Clinical Genetics Referral Acceptance 
In approximately 80% of cases, respondents indicated they would accept a referral to their preferred 
service if offered. The influence of attribute levels on choice is apparent in the impact on the probability 




probability of a service option being chosen when each attribute level is present, given all other possible 
service combinations, and based on the choice relationship in Model 3. This shows that having only one 
appointment, within two weeks, with both a clinical geneticist and genetic counselor, and both verbal and 
web-based information has the greatest impact on the probability of a service being chosen. Health 
professional type (i.e., presence of both genetics health professionals), was the most influential attribute. 
 
[Insert Figure 3 about here] 
 
Based on the relationships in Model 3, it is also possible to predict the probability of service use based on 
a combination of attribute levels that might apply. Four possible service models (Services 1-4), including 
the service associated with the most influential attribute levels, were chosen to test possible variations 
from the current service delivery model (Table 2). The probability of choosing each of these services was 
tested against that of the current model (Service 5). The resulting probabilities of uptake for each service 
(Services 1-4) in pairwise comparisons with Service 5 show that Service 1 was most popular; 93% of 
respondents indicated they would attend this service, if available. This is consistent with the attribute 
levels shown to be most favorable in Model 3.   
 
[Insert Table 2 about here] 
 
DISCUSSION 
An important determinant of people’s experience of healthcare is how health services are delivered. This 
includes who provides the health service, in what format, how often, and when. Understanding how 
individuals might choose to participate in healthcare based on each of these factors is essential if we are to 
provide services that maximize participation in care. DCEs have been used to investigate these questions 
in several areas of healthcare, including participation in genetic screening and carrier testing.e.g.32 To our 




services tailored to congenital heart disease. This approach allows estimation of preferences for novel 
technologies and health services prior to, rather than following, their implementation. This enables service 
design to better reflect the preferences of future users before implementation, maximizing potential 
uptake and impact. The challenge for service providers will be to design services that best match these 
preferences. Achieving rapid appointment times may be particularly challenging, given the demand for 
pediatric cardio-genetics services,24-26 the high prevalence of CHD compared to other congenital 
anomalies,1 and the limited number of specialists to provide such services. Awareness of the burden this 
could place on under-staffed genetics services, and strategies for addressing this, are much needed and 
reflect an issue affecting current practice models and the clinical genetics workforce globally.   
 
This study provides further evidence of a high willingness to access pediatric cardio-genetics services.24 
Parents of children with CHD have an overwhelming preference for cardio-genetics services featuring: (a) 
one appointment, (b) with both a clinical geneticist and genetic counselor, (c) providing verbal and web-
based information, (d) and occurring within two weeks. If offered this service, 93% of respondents 
indicated they would attend. This is an important finding, because it indicates that providing genetic 
counseling with reduced appointment waiting time would result in attendance by almost all parents 
offered a referral. Independent of patient preference, there are obvious advantages to this approach. While 
the diagnosis of CHD-associated syndromes is the province of the clinical geneticist, emphasis on both 
medical and emotional aspects of genetic assessment for CHD is consistent with the profound 
psychological consequences of complex CHD reported by parents.33 Access to counseling and support of 
the type a genetic counselor can provide is likely to improve parents’ understanding of, and psychological 
adaptation to, their child’s heart condition26 and is consistent with evidence on the clinical benefits of, and 
patients’ preferences for, integrated interdisciplinary healthcare.33  
 
DCEs examining preferences for genetic services in other clinical settings (e.g., cancer, mental health), 




delivery,34 and information provision.32 Peacock et al. investigated women’s preferences for genetic 
counseling for breast and ovarian cancer risk, focusing on amount of information provided, counseling in 
preparation for test outcomes, guidance regarding surveillance and risk management, and genetic testing 
recommendations.32 Respondents valued information provision above all other factors, with women 
valuing information about cancer genetics nine times more than direct guidance regarding whether to 
undergo genetic testing. This is consistent with the goals of genetic counseling, which include providing 
information about disease and genetic factors that may influence risk, symptomatology or treatment, and 
facilitating autonomous health decision-making. Our finding that respondents preferred genetics 
information in both verbal and web-based formats is also consistent with previous research. In a study by 
Kasparian et al.,35 parents of children with CHD reported a strong desire for web-based healthcare 
information, or eHealth, recommended by their pediatric cardiac team. Web-based information was 
reported to influence medical decision-making for over half the sample, despite relatively low levels of 
eHealth literacy.35 
 
Several study limitations must also be considered. Unlike some DCEs in clinical genetics, we did not 
include cost in our study because pediatric cardio-genetics services are offered free of charge within our 
center, as in most Australian centers. This means it is not possible to estimate parents’ willingness to pay 
for the presence of two clinicians, or shorter waiting times, for example. Previous DCEs have also 
considered the impact of genetic test results on respondents’ preferences. In contrast, our research 
investigated parents’ decision to attend a pediatric cardio-genetics service, irrespective of genetic testing 
availability. In so doing, we focused on how such services might be best structured, rather than on the 
nature of information provided within those services. This was considered important in a first study on 
parents’ preferences for clinical genetics services for CHD, given limited available evidence on the 
clinical implications of such information and the rapidly evolving nature of the field.9 We are not aware 
of evidence to suggest systematic differences in men and women’s DCE responses, but acknowledge the 




investigating the preferences of parents of more recently diagnosed children, of adolescents and young 
people with CHD, and of bereaved families, will broaden the evidence from which to inform best practice 
in pediatric cardio-genetics. 
 
Potential practice models in pediatric cardio-genetics 
Our findings suggest at least three potential models for the integration of clinical genetics services into 
CHD care, each with strengths and weaknesses. The model most strongly supported by our results is one 
in which all children with CHD are referred to an interdisciplinary pediatric cardio-genetics service, 
ideally co-located with the referring cardiac center. Genetics assessment would include consideration of 
family history, potential teratogenic exposures and examination for features suggestive of an underlying 
syndromal cause. Although most CHD is multifactorial in causation, parents (particularly those 
considering further children) would benefit from reassurance around exposures during pregnancy and 
empiric recurrence risks, informed by expert opinion about the likelihood of a Mendelian cause. Genetic 
counseling would be offered hand-in-hand with medical evaluation, and would be tailored to meet the 
psychosocial needs of families, including referral to medical psychology services, when indicated. It is, 
however, unlikely that such a model could deliver the speed of appointment preferred by parents, and the 
resource and funding implications are prohibitive.  
 
Given these constraints, other models require consideration. There is a strong case for further 
development of genetic counselors’ role in CHD care.26 There are existing models in cardiac genetics 
(e.g. cardiomyopathies, disorders of cardiac rhythm) for participation of genetic counselors in 
cardiologist-led services,36 with consultation with clinical geneticists as required. Some upskilling of 
pediatric cardiologists and cardiac surgeons would be needed, to ensure equitable access and to triage 
patients for genetics review. While this would not directly match the preferred model suggested by our 
data, it would meet some of the requirements - particularly for speed and genetic counselor involvement. 





Lastly, consideration could be given to focusing almost entirely on empowering pediatric cardiologists 
and cardiac surgeons to take on a substantial part of the genetics assessment and even counseling. While 
this group of health professionals has considerable relevant knowledge and immediate access to the 
patient, it seems unlikely that most cardiologists would have time for these tasks. At a minimum, a 
proportion of the required information could be streamlined through the use of eHealth (online) 
resources.35 These would not replace clinical assessment or care provided by genetics professionals, but 
could provide an educational grounding to facilitate clinical interactions and support informed decision-
making. eHealth resources, developed by an interdisciplinary team, also have the advantages of being 
easy for patients and families to re-access at various points throughout the care trajectory, and of being 
inexpensive for health professionals to maintain and update as genetic knowledge and technologies 
evolve. Irrespective of the service model, our data suggest best practice is for every pediatric cardiac 
center to have access to clinical genetics services and resources for CHD. 
 
CONCLUSION 
As the molecular basis of CHD comes into sharper focus, cardiac genetics services are likely to play an 
increasingly important clinical role. Research shows that genetic factors play a role in almost all parents’ 
causal attributions for CHD.24 Understanding families’ preferences for novel genetic technologies and 
services prior to, rather than following, their implementation is vital for informing health policy and 
shaping future health services. Modeling the factors that influence engagement with cardiac genetics 
services can ensure that such services are designed to meet participation targets. In this study, we found 
parents espoused a ‘tell me once, tell me soon’ model of clinical genetics services for CHD. Gaining a 
deeper and more precise understanding of the aspects parents value most in relation to these services - and 
developing, testing and implementing innovative practice models to improve service access, use, 
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Figure 1. Example of a choice task offered to participants. Each participant completed nine such tasks. 
Hypothetical services differed on four attributes: appointment format, health professionals who provide 
the service, appointment waiting time, and the format in which information is provided. In each task, 
participants were asked to choose between two cardiac genetics service models. Participants were also 
asked to indicate whether they would accept a referral to attend their preferred service. 
 
 
Figure 2.  Results of the mixed logit analysis (Model 3), illustrating parents’ (N=100) preferences 
for genetics services for congenital heart disease. The top portion of the figure (above the dotted line) 
shows the mean coefficient values, while the bottom portion (below the dotted line) shows the extent of 
deviation (standard deviation) among individual for those values. 
 
 
Figure 3.  Influence of the four attributes on mean probability of choice. Base levels for each 
attribute are presented in green. Note: The mean probability of choice at each attribute level was 
generated by non-parametric bootstrapping of predicted probabilities, given the overall model results and 
over 1,000 replications. This method utilizes the likelihood of choice from the mixed logit without a 
constant.   
 
Conflict of Interests Statement 
The authors declare no conflict of interest. 
Conflict of Interest Statement
Figure 1. Example of a choice task offered to participants. Each participant completed nine such tasks. 
Hypothetical services differed on four attributes: appointment format, health professionals who provide 
the service, appointment waiting time, and the format in which information is provided. In each task, 
participants were asked to choose between two cardiac genetics service models. Participants were also 
asked to indicate whether they would accept a referral to attend their preferred service. 
 
Which type of appointment would you prefer? 
 
 APPOINTMENT A APPOINTMENT B 
Appointment 
Format 
One appointment and ongoing support 
provided over the telephone 
One appointment only 
Health 
Professional 
Clinical Geneticist  
and Genetic Counsellor 
Clinical Geneticist only 
Waiting 
Time 
Six weeks Six months 
Information 
Format 
Verbal information                                                   
and an information booklet to take home 
Verbal information                                                
and the link to a relevant website 
 
Which would you prefer?   Appointment A        Appointment B       
 
If your preferred appointment was offered,        Yes                           No                           
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The top portion of the figure (above the dotted line) shows the mean coefficient values, while the bottom portion (below the dotted line)
shows the extent of deviation (standard deviation) among respondents for those values.
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Figure 3
Table 1.  Demographic characteristics presented separately for the total sample (N=114) 
and DCE respondents (N=100). 
Level 
All Participants  
N=114 (%) 
Completed DCE  
N=100 (%) 
Age    
≥25 years 4 (3.5) 3 (3.0) 
26 to 35 years 46 (40.4) 42 (42.0) 
36 to 45 years 55 (48.3) 50 (50.0) 
≤46 years 9 (7.9) 5 (5.0) 
Education   
Tertiary 57 (50.0) 51 (51.0) 
No tertiary 56 (49.1) 48 (48.0) 
Not reported 1 (0.9) 1 (1.0) 
Gross annual household income   
Below national average 48 (42.1) 40 (40.0) 
Above national average 50 (43.9) 48 (48.0) 
Not reported 16 (14) 12 (12.0) 
Birthplace 
 Australia 83 (72.8) 79 (79.0) 
Elsewhere 31 (27.2) 21 (21.0) 
Language spoken at home 
English 101 (88.6) 90 (90.0) 
Other 13 (11.4) 10 (10.0) 
Relationship to child with CHD 
Mother 91 (79.8) 80 (80.0) 
Father 20 (17.5) 19 (19.0) 
Other 1 (0.9) 0 
Not reported 2 (1.8) 1 (1.0) 
Residence at time of childbirth 
Metropolitan NSW 80 (70.2) 70 (70.0) 
Regional/Rural NSW 31 (27.2) 27 (27.0) 
Overseas 3 (2.6) 3 (3.0) 
Child chromosomal abnormality  
No 74 (64.9) 65 (65.0) 
Yes/Unsure 39 (34.2) 34 (34.0) 
Not reported 1 (0.9) 1 (1.0) 
Previously attended a genetics service for CHD 
No  89 (78.1) 76 (76.0) 
Yes 25 (21.9) 24 (24.0) 
Table 1
 
Table 2. Predicted service use, indicating the probability of each service being used, based on the relationships observed  
from the mixed logit regression model without a constant. 
 




































2 weeks 6 months 6 months 2 weeks 6 months 
Information 
Format 
Verbal and  
web-based 
information 
Verbal information  
and booklet 
Verbal information  
only 
Verbal and  
web-based 
information 














Probabilities of service uptake relative to Service 5 (probability of uptake for Service 5 shown in brackets). 
Table 2
Supplementary Table A. The four attributes, each with three levels, included in the discrete 
choice experiment examining parents’ preferences for pediatric cardio-genetics services.  
 
Attribute 1:   APPOINTMENT FORMAT 
The number of appointments offered may vary. 
Level 1:   One appointment only. 
Level 2:   One appointment and one follow-up appointment.  
Level 3:   One appointment and ongoing support provided by telephone. 
 
Attribute 2:   HEALTH PROFESSIONALS  
A Clinical Geneticist is a doctor who specializes in the assessment and medical care of people with 
a genetic condition. A Genetic Counselor has specialist training in providing information, 
education and counseling to individuals and families affected by a genetic condition.  
Level 1:   Clinical Geneticist only. 
Level 2:   Clinical Geneticist and Genetic Counselor. 
Level 3:   Genetic Counselor only. 
 
Attribute 3:   APPOINTMENT WAITING TIME 
The length of time that families may need to wait to see a Clinical Geneticist and/or Genetic 
Counselor may also vary. 
Level 1:   Two weeks. 
Level 2:   Six weeks. 
Level 3:   Six months. 
 
Attribute 4:   INFORMATION FORMAT 
Information provided in a genetics appointment can be communicated in a variety of ways. Verbal 
information simply involves listening to what is said during the appointment. Families may also 
want to take home some written information, or be given a link to a relevant website. 
Level 1:   Verbal information only. 
Level 2:   Verbal information and an information booklet to take home. 




Supplementary Table B.  Results of the conditional logit and mixed logit regression analyses, each examined without (Models 1 and 3), and with 
(Models 2 and 4), a constant to test the potential for position bias. 
 Conditional Logit Mixed Logit 
 MODEL 1 MODEL 2 MODEL 3 MODEL 4 
Coefficient Means   
Appointment Format: One appointment only   
Initial and follow-up appointments -0.592 (0.123)**  -0.578 (0.128)** -0.737 (0.176)** -0.751 (0.195)** 
Ongoing appointments -0.535 (0.121)** -0.550 (0.117)** -0.628 (0.177)** -0.694 (0.194)** 
     
Health Professional: Clinical geneticist    
Genetic counselor 0.068 (0.082) 0.104 (0.084) 0.123 (0.116) 0.184 (0.131) 
Clinical geneticist and genetic counselor 1.139 (0.114)** 1.183 (0.125)** 1.543 (0.290)** 1.687 (0.342)** 
     
Appointment Waiting Time: 6 months    
6 weeks 0.138 (0.117) 0.090 (0.120) 0.112 (0.159) 0.066 (0.169) 
2 weeks 0.584 (0.119)** 0.545 (0.114)** 0.723 (0.197)** 0.725 (0.210)** 
    
Information Format: Verbal only    
Verbal and booklet -0.231 (0.108)* -0.204 (0.112) -0.251 (0.156) -0.234 (0.167) 
Verbal and web-based (eHealth) 0.276 (0.109)* 0.351 (0.117)** 0.448 (0.174)* 0.570 (0.202)** 
     
Constant  0.237 (0.074)** 0.341 (0.108)** 
 
Supplementary Table B
Coefficient Standard Deviations 
Appointment Format: One appointment only    
Initial and follow-up appointments   0.818 (0.309)** 0.974 (0.334)** 
Ongoing appointments   0.848 (0.288)** 0.873 (0.316)** 
     
Health Professional: Clinical geneticist    
Genetic counselor   0.012 (0.044) 0.020 (0.037) 
Clinical geneticist and genetic counselor   0.674 (0.320)* 0.766 (0.319)* 
     
Appointment Waiting Time: 6 months    
6 weeks   0.793 (0.281)** 0.925 (0.306)** 
2 weeks   0.328 (0.466) 0.387 (0.436) 
     
Information Format: Verbal only    
Verbal and booklet   0.746 (0.243)** 0.799 (0.267)** 
Verbal and web-based (eHealth)   -0.152 (0.760) -0.294 (0.478) 
     
Observations 1,800 1,800 1,800 1,800 
Individuals 100 100 100 100 
Pseudo R-Squared 0.18 0.19 0.19 0.21 
Wald Chi 144.90 124.70 36.33 34.12 
df 8 9 8 9 
p-value 0.00 0.00 0.00 0.00 
Log-likelihood -508.81 -504.42 -499.80 -493.74 
 
 *p<0.05, **p<0.01, ***p<0.001    
 The omitted level for each independent variable is shown in bold and underlined typeface, alongside the category name. 
Pseudo R-squared for Models 3 and 4 estimated as 1-(log-likelihoodm/log-likelihoodc), where m denotes the relevant model and c denotes a model 
with a constant only random term. df: degrees of freedom. 
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1. How was the sample size chosen to ensure 
adequate power to detect a pre-specified effect 
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2. Describe inclusion/exclusion criteria if samples or 
animals were excluded from the analysis. Were 




3. If a method of randomization was used to 
determine how samples/animals were allocated 
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Page 6: Parents or guardians of a living child diagnosed with a 
congenital cardiac malformation between 2000-2009 and who had 
undergone cardiac surgery, were identified for study participation 
via the databases of the Department of Cardiology at the Sydney 
Children’s Hospital, Australia. Fully consented and contactable 
individuals were eligible for participation if they were aged over 18 
years and could complete the study survey in English. To limit the 
burden on families, only one parent per family was invited to 
participate. The choice regarding who took part in the survey was 
left up to the individual families.
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Page 8: Heterogeneity in preferences was explored by applying the 
method described by Hole,34 which estimates the extent to which 
attributes influence choice (reported as means), as well as the 
extent to which respondents differ in the influence of those 
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Page 8: DCE analysis exploits the relationship between respondents’ 
choices and the choice profiles, revealing the impact on choice of 
differences between the attributes for the options being compared. 
Our analysis adopted this approach, focusing on the mean choice 
coefficients across respondents using an initial multinomial logit 
analysis, then a mixed logit analysis to incorporate the extent to 
which there was h terogen ity across respondents in what 
influenced their choices. For each of the ultinomial logit and 
mixed logit analyses, two models were specified; with and without 
a co stant term. A c sta t term was included in two of the models 
(Model 2 and 4), to test whether respondents were systematically 
choosing th  left or right-hand profile in each choice set presented. 
Only respondents who completed all nine choice sets were included 
in the analysis. The impact on the results of excluding respondents 
who completed fewer than nine choice sets was tested in a 
sensitivity analysis. An additional sensitivity analysis was carried out 
to examine the impact on preferences of respondents having 
previously attended a cardiac genetics service. The likelihood of 
service use was examined using the results of the mixed logit 
analysis, using pairwise comparisons to estimate the probability 
that respondents would use one of four new service models 
compared with the current approach to cardiac genetics service 
provision. All analyses were carried out using StataCorp statistical 
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